IMMUNITYBIO INC (IBRX) Stock Overview
USA - NASDAQ:IBRX - US45256X1037 - Common Stock
IBRX Key Statistics, Chart & Performance
The current stock price of IBRX is 2.76 USD. In the past month the price increased by 21.05%. In the past year, price decreased by -21.59%.
IBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.85 | 390.07B | ||
| AMGN | AMGEN INC | 12.6 | 147.89B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 139.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.85 | 99.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.21B | ||
| ARGX | ARGENX SE - ADR | 79.22 | 44.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.79 | 39.49B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About IBRX
Company Profile
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 685 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Company Info
IMMUNITYBIO INC
3530 John Hopkins Court
San Diego CALIFORNIA 92121 US
CEO: Richard Adcock
Employees: 685
Phone: 18446965235
IMMUNITYBIO INC / IBRX FAQ
What is the stock price of IMMUNITYBIO INC today?
The current stock price of IBRX is 2.76 USD. The price decreased by -1.78% in the last trading session.
What is the ticker symbol for IMMUNITYBIO INC stock?
The exchange symbol of IMMUNITYBIO INC is IBRX and it is listed on the Nasdaq exchange.
On which exchange is IBRX stock listed?
IBRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNITYBIO INC stock?
11 analysts have analysed IBRX and the average price target is 10.4 USD. This implies a price increase of 276.96% is expected in the next year compared to the current price of 2.76. Check the IMMUNITYBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNITYBIO INC worth?
IMMUNITYBIO INC (IBRX) has a market capitalization of 2.61B USD. This makes IBRX a Mid Cap stock.
How many employees does IMMUNITYBIO INC have?
IMMUNITYBIO INC (IBRX) currently has 685 employees.
What are the support and resistance levels for IMMUNITYBIO INC (IBRX) stock?
IMMUNITYBIO INC (IBRX) has a support level at 2.59 and a resistance level at 3.02. Check the full technical report for a detailed analysis of IBRX support and resistance levels.
Is IMMUNITYBIO INC (IBRX) expected to grow?
The Revenue of IMMUNITYBIO INC (IBRX) is expected to grow by 603.46% in the next year. Check the estimates tab for more information on the IBRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNITYBIO INC (IBRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IBRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IBRX, evaluating the profitability, health, valuation and growth aspects
- IMMUNITYBIO INC (IBRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNITYBIO INC (IBRX) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNITYBIO INC (IBRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNITYBIO INC (IBRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNITYBIO INC (IBRX) Stock Chart to make your own analysis
- IMMUNITYBIO INC (IBRX) Latest news and press-releases to stay up to date.
Does IMMUNITYBIO INC (IBRX) stock pay dividends?
IBRX does not pay a dividend.
When does IMMUNITYBIO INC (IBRX) report earnings?
IMMUNITYBIO INC (IBRX) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of IMMUNITYBIO INC (IBRX)?
IMMUNITYBIO INC (IBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.46).
What is the Short Interest ratio of IMMUNITYBIO INC (IBRX) stock?
The outstanding short interest for IMMUNITYBIO INC (IBRX) is 25.88% of its float. Check the ownership tab for more information on the IBRX short interest.
IBRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IBRX. When comparing the yearly performance of all stocks, IBRX is a bad performer in the overall market: 85.73% of all stocks are doing better.
IBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IBRX. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative.
IBRX Financial Highlights
Over the last trailing twelve months IBRX reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS increased by 51.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.3% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IBRX Forecast & Estimates
11 analysts have analysed IBRX and the average price target is 10.4 USD. This implies a price increase of 276.96% is expected in the next year compared to the current price of 2.76.
For the next year, analysts expect an EPS growth of 13.89% and a revenue growth 603.46% for IBRX